The potential beneficial effect of exenatide on cisplatin induced nephrotoxicity in non-diabetic rats

  • Authors

    • Eman Abdel-Mohsen Abdel-Aziz Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Benha University, Benha, Egypt
    • Sahar M. Abo El Wafa Department of Pharmacology,Faculty of Medicine, Benha University, Benha, Egypt.
    2020-03-25
    https://doi.org/10.14419/ijpt.v8i1.30454
  • Antioxidant, Cisplatin, Exenatide, Nephrotoxicity.

  • Abstract

    Background: Cisplatin is a major antitumor drug used for treatment of solid tumors. Nephrotoxicity is its main limiting side effect. Exenatide is described as an incretin mimetic polypeptide, it acts as a GLP-1 receptor agonist and its insulinotropic activity is mediated through binding to and stimulation of GLP-1 receptors on human pancreatic β-cells. Aim: the present work was designed to study the effect of exenatide on experimentally cisplatin induced nephropathy in non- diabetic rats. Materials and Methods: Thirty two male adult Sprague Dawley rats randomly divided into four groups, each consisted of 8 animals, and distributed as follows: Group I: (control) normal group and received saline vehicle. Group II: (cisplatin) group includes rats injected intraperitoneally by a single dose of cisplatin (6 mg/kg) to induce nephrotoxicity, received no treatment and were sacrificed 7 days after cisplatin administration. Group III: (exenatide) group: rats treated by exenatide (10 mg/kg/day s.c.) for 4 weeks. Group IV: (exenatide+cisplatin) group: rats treated by exenatide (10 mg/kg/day s.c.) for 4 weeks before induction of nephrotoxicity by cisplatin. The following parameters were measured: fasting blood glucose, serum urea, serum creatinine, reduced glutathion (GSH) level in the renal tissue, tumor necrosis factor-α (TNF-α) level in the renal tissue, renal blood flow changes and histopathological changes of the kidney. Results: Pretreatment with exenatide resulted in significant reduction in serum urea, serum creatinine level and renal TNF- α level compared to cisplatin group but still significantly higher than control group with significant increase in renal GSH level and renal blood flow compared to cisplatin group but still also significantly lower than control group. Cisplatin group showing tubular degeneration with infiltration of inflammatory cells while pretreatment with exenatide showing certain improvement in general histological structure with mild tubular degeneration and less inflammatory cell infiltration. Conclusion: it can be concluded that the use of exenatide improved the biochemical and histopathological changes that occur in the renal tissue by cisplatin.

     


     

  • References

    1. [1] Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Nahour G, Bourbouze R, Jacobs C, Deray G (2000): Erythropoietin enhances recovery after cisplatin induced acute renal failure in the rat. Nephrology Dialysis Transplantation. 16: 932-938. https://doi.org/10.1093/ndt/16.5.932.

      [2] Bhoomika M, Patel N, Deepak D (2013): Combination of Telmisartan with Cisplatin Controls Oral Cancer Cachexia in Rats. BioMed Research International. Article ID 642848, 10 pages. https://doi.org/10.1155/2013/642848.

      [3] Chaudhuri Ajay, Ghanim Husam, Vora Mehul, Sia Chang Ling, Korzeniewski Kelly, Dhindsa Sandeep, Makdissi Antoine, Dandona Paresh (2012): Exenatide Exerts a Potent Antiinflammatory Effect, The Journal of Clinical Endocrinology & Metabolism.97: 198–207. https://doi.org/10.1210/jc.2011-1508.

      [4] Decloedt E and Maartens G (2011): Drug-induced renal injury. The kidney plays an important role in the elimination of many drugs and their metabolites.CME.29: 252-256.

      [5] Dury RAB and Wallington EA (1967): Carleton Histological Technique. 4th ed. Oxford University Press, Oxford, P. 129.

      [6] Efendic S, Karlander S, Vranic M (1988): Mild type II diabetes markedly increases glucose cycling in the postabsorptive state and during glucose infusion irrespective of obesity. J Clin Invest., 81: 1953- 1961. https://doi.org/10.1172/JCI113543.

      [7] El-Gohary OA and Said MA (2015): Protective effect of exenatide (glucagon-like peptide-1 receptor agonist) on renal ischemia–reperfusion injury in diabetic rats. Benha Med J; 33:24-30. https://doi.org/10.4103/1110-208X.194384.

      [8] Hasiyeti L, Yanzhang L, Wenpeng C, Xiaopeng T, Heather N, Xinyu Q, Shuxia W (2013): Increasing cGMP-dependent protein kinase I activity attenuates cisplatin-induced kidney injury through protection of mitochondria function.Am J Physiol Renal Physiol.305: 881-900. https://doi.org/10.1152/ajprenal.00192.2013.

      [9] Haywood JR, Sahffer RA, Fastenow C (1981): Regional blood flow measurement with Pulsed doppler flowmeter in conscious rats. Am J Physical.241: 273-278. https://doi.org/10.1152/ajpheart.1981.241.2.H273.

      [10] Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. (2017): Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 28; 377(13):1228-1239. https://doi.org/10.1056/NEJMoa1612917.

      [11] Kaplan A (1984): Urea. Kaplan A et al. Clin Chem the C. V Mosby Co.St Louis Toronto Princeton. 1257-1260 and 437 and 418.

      [12] Koole C, Reynolds CA, Mobarec JC, Hick C, Sexton PM, Sakmar TP (April 2017): "Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R)". The Journal of Biological Chemistry. 292 (17): 7131–7144. https://doi.org/10.1074/jbc.M117.779496.

      [13] Marcel H. A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H. H. Kramer Michaela Diamant, Jaap A. Joles, Daniël H. van Raalte (2016): Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes Metab; 18: 178-185. https://doi.org/10.1111/dom.12601.

      [14] Mohamed A A, Ashraf M, Abdel-Moneim O, Elmenshawy M, Mohamed A E (2014): Hemin Attenuates Cisplatin-Induced Acute Renal Injury in Male Rats. Oxidative Medicine and Cellular Longevity. Article ID 476430, 9 pages. https://doi.org/10.1155/2014/476430.

      [15] Murray RL (1984): creatinine. Kaplan A et al. Clin Chem The C. V Mosby Co.St Louis Toronto Princeton. , 1261-1266 and 418.

      [16] Noori S, Nasir K, Mahboob T (2009): Effect of cocoa powder on oxidant /antioxidant in liver, heart and kidney tissue of rats. The Journal of Animal & Plant Sciences.4: 174-178.

      [17] Ozkok A and Charles LE (2014): Pathophysiology of Cisplatin-Induced Acute Kidney Injury. BioMed Research International. Article ID 967826, 17 pages. https://doi.org/10.1155/2014/967826.

      [18] Pan H, Shen K, Wang X, Meng H, Wang C, Jin B (2014): Protective Effect of Metalloporphyrins against Cisplatin-Induced Kidney Injury in Mice. J Am Soc Nephrol. 12: 2683–2690.

      [19] Parasuraman S, Raveendran R, Kesavan R (2010): Blood sample collection in small laboratory animals. J Pharmacol . Pharmacother. 1: 87–93. https://doi.org/10.4103/0976-500X.72350.

      [20] Saad SY and Al-Rikabi AC (2002): Protection Effects of Taurine Supplementation against Cisplatin-Induced Nephrotoxicity in Rats.Chemotherapy.48:42–48. https://doi.org/10.1159/000048587.

      [21] Tanaka K, Masaki Y, Tanaka M, Miyazaki M, Enjoji M, Nakamuta M, et al. (2014): Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in non-diabetic rats. World J Gastroenterol; 20(10): 2653-2663. https://doi.org/10.3748/wjg.v20.i10.2653.

      [22] Tetsuhiro Tanaka1, Yoshiki Higashijima1, Takehiko Wada1 and Masaomi Nangaku (2014): The potential for renoprotection with incretin-base drugs Kidney International. 86: 701–711. https://doi.org/10.1038/ki.2014.236.

      [23] Tusgaard B, Nørregaard R, Jensen A M, Wang G, Topcu S O, Wang Y, Nielsen S, Frøkiaer J (2011): Cisplatin decreases renal cyclooxygenase-2 expression and activity in rats. Acta physiologica (Oxford, England) .202: 79-90. https://doi.org/10.1111/j.1748-1716.2011.02257.x.

      [24] Wang X, Li Z, Huang X, Li F, Liu J, Li Z, Bai D)2019:( An experimental study of exenatide effects on renal injury in diabetic rats. Acta Cir. Bras., 34 (1): e20190010000001. https://doi.org/10.1590/s0102-865020190010000001.

      [25] Xu Y, Wei Z, Zhang Z, Xing Q, Hu P, Zhang X, et al. (2009): No association of the insulin gene VNTR polymorphism with polycystic ovary syndrome in a Han Chinese population. Reproductive Biology and Endocrinology, 7: 1–5. https://doi.org/10.1186/1477-7827-7-141.

      [26] Yao X, Panichpisal K, Kurtzman N, Nugent K (2007): Cisplatin Nephrotoxicity: A Review. Am J Med Sci. 334:115–124. https://doi.org/10.1097/MAJ.0b013e31812dfe1e.

  • Downloads

  • How to Cite

    Abdel-Mohsen Abdel-Aziz, E., & M. Abo El Wafa, S. (2020). The potential beneficial effect of exenatide on cisplatin induced nephrotoxicity in non-diabetic rats. International Journal of Pharmacology and Toxicology, 8(1), 49-53. https://doi.org/10.14419/ijpt.v8i1.30454

    Received date: 2020-02-21

    Accepted date: 2020-03-14

    Published date: 2020-03-25